{"id":"rhg-csf-peg-rhg-csf","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Bone pain"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This is achieved by mimicking the action of granulocyte colony-stimulating factor (G-CSF), a naturally occurring protein that promotes the growth and differentiation of neutrophils, a type of white blood cell. The addition of polyethylene glycol (PEG) to rhG-CSF increases its half-life, allowing for more sustained and effective stimulation of white blood cell production.","oneSentence":"rhG-CSF/PEG-rhG-CSF stimulates the production of white blood cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:00.210Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neutropenia in patients undergoing chemotherapy"}]},"trialDetails":[{"nctId":"NCT07020533","phase":"PHASE1","title":"A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-05-08","conditions":"Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":46},{"nctId":"NCT06709495","phase":"PHASE1, PHASE2","title":"Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas","status":"RECRUITING","sponsor":"David S Shulman, MD","startDate":"2025-01-27","conditions":"Sarcoma, Sarcoma, Ewing, Desmoplastic Small Round Cell Tumor","enrollment":63},{"nctId":"NCT07101445","phase":"PHASE4","title":"Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-09-24","conditions":"Multiple Myeloma","enrollment":94},{"nctId":"NCT07046078","phase":"PHASE2","title":"Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-09-26","conditions":"Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia","enrollment":20},{"nctId":"NCT04370301","phase":"PHASE2","title":"Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-02-09","conditions":"Primary Myelofibrosis, Secondary Myelofibrosis","enrollment":20},{"nctId":"NCT06520163","phase":"PHASE3","title":"Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2024-08-01","conditions":"Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization","enrollment":99},{"nctId":"NCT04871607","phase":"PHASE2","title":"Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-11-02","conditions":"Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma","enrollment":33},{"nctId":"NCT03670966","phase":"PHASE1, PHASE2","title":"211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-07-10","conditions":"Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia in Remission","enrollment":30},{"nctId":"NCT04797767","phase":"PHASE1, PHASE2","title":"Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms","status":"RECRUITING","sponsor":"University of Washington","startDate":"2022-02-04","conditions":"Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia","enrollment":62},{"nctId":"NCT04195945","phase":"PHASE2","title":"CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-03-11","conditions":"Acute Myeloid Leukemia, Myeloid Neoplasm","enrollment":60},{"nctId":"NCT06924385","phase":"PHASE1","title":"Safety, Tolerability, and PK/PD of Telpegfilgrastim Injection in Non-pregnant Females of Childbearing","status":"RECRUITING","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2025-04-06","conditions":"Preeclampsia","enrollment":30},{"nctId":"NCT06893796","phase":"PHASE1","title":"Safety, Tolerability, and PK/PD of Telpegfilgrastim in Premenopausal Non-pregnant Females","status":"COMPLETED","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2025-03-26","conditions":"Preeclampsia","enrollment":18},{"nctId":"NCT06958614","phase":"","title":"Prophylactic PEG-rhG-CSF During cCRT in LA-NSCLC","status":"COMPLETED","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2019-09-02","conditions":"Stage II-III Non-small Cell Lung Cancer, Concurrent Chemotherapy, Conditions Influencing Health Status","enrollment":213},{"nctId":"NCT06926751","phase":"PHASE2","title":"Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-04-07","conditions":"Solid Tumors, Children, Adolescent","enrollment":132},{"nctId":"NCT03844360","phase":"PHASE4","title":"Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease","status":"RECRUITING","sponsor":"Wei Zhao","startDate":"2016-01-31","conditions":"Hematological Neoplasms","enrollment":1500},{"nctId":"NCT06616571","phase":"PHASE4","title":"Compare the Efficacy and Safety of QL0605 Injections at Different Timepoints","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2024-09-19","conditions":"Chemotherapy-Induced Febrile Neutropenia","enrollment":336},{"nctId":"NCT06520176","phase":"PHASE3","title":"Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2024-08","conditions":"Multiple Myeloma, Hematopoietic Stem Cell Mobilization","enrollment":99},{"nctId":"NCT05536154","phase":"NA","title":"Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2022-11-01","conditions":"Lymphoma, Multiple Myeloma","enrollment":68},{"nctId":"NCT05970185","phase":"EARLY_PHASE1","title":"The Value of Peripheral Blood CD34+ Cell Dynamics Monitoring in Autologous Hematopoietic Stem Cell Transplant Mobilization","status":"UNKNOWN","sponsor":"Zhongnan Hospital","startDate":"2024-02-01","conditions":"Granulocyte Colony-Stimulating Factor","enrollment":40},{"nctId":"NCT03858166","phase":"PHASE4","title":"Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer","status":"TERMINATED","sponsor":"Shandong University","startDate":"2017-12-01","conditions":"Adjuvant Chemotherapy, Ovarian Neoplasms, Ovarian Cancer","enrollment":68},{"nctId":"NCT04196010","phase":"PHASE1","title":"Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms","status":"TERMINATED","sponsor":"University of Washington","startDate":"2020-05-08","conditions":"Myeloid Neoplasm, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":13},{"nctId":"NCT05510089","phase":"NA","title":"Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies","status":"UNKNOWN","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2022-09-01","conditions":"Hematological Malignancy","enrollment":62},{"nctId":"NCT06060080","phase":"NA","title":"Efficacy and Safety of PEG-rhG-CSF Injection for Neutrophil Reconstitution Following AHSCT in Lymphoma/Multiple Myeloma","status":"UNKNOWN","sponsor":"Yao Liu","startDate":"2022-04-22","conditions":"Lymphoma, Multiple Myeloma","enrollment":7},{"nctId":"NCT06026995","phase":"PHASE4","title":"Clinical Study on PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells","status":"UNKNOWN","sponsor":"Chongqing University Cancer Hospital","startDate":"2022-03-01","conditions":"Lymphoma","enrollment":174},{"nctId":"NCT04542356","phase":"PHASE2","title":"Study on the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia During Concurrent Chemoradiotherapy of Cervical Cancer","status":"COMPLETED","sponsor":"Chongqing University Cancer Hospital","startDate":"2018-08-01","conditions":"Cervical Cancer","enrollment":60},{"nctId":"NCT03531918","phase":"PHASE1, PHASE2","title":"Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2018-09-14","conditions":"Acute Myeloid Leukemia","enrollment":66},{"nctId":"NCT05834751","phase":"NA","title":"the Efficacy and Safety of PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells in Lymphoma","status":"UNKNOWN","sponsor":"Ou Bai, MD/PHD","startDate":"2023-05-01","conditions":"Lymphoma","enrollment":144},{"nctId":"NCT04477616","phase":"PHASE2","title":"Injection Regimen Trial of PEG-rhG-CSF During Breast Cancer Chemotherapy","status":"COMPLETED","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2021-07-13","conditions":"Breast Cancer","enrollment":160},{"nctId":"NCT04554056","phase":"PHASE2, PHASE3","title":"Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF","status":"COMPLETED","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2020-09-21","conditions":"Breast Cancer Female","enrollment":586},{"nctId":"NCT05531279","phase":"NA","title":"A Study of PEG-rhG-CSF and rhG-CSF Used for Aplastic Anemia Granulocyte Deficiency","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-06-05","conditions":"Severe Aplastic Anemia","enrollment":45},{"nctId":"NCT04460508","phase":"PHASE2","title":"Mecapegfilgrastim(PEG-G-CSF) for Prophylaxis of Chemotherapy-induced Neutropenia in Patients With Lymphoma","status":"UNKNOWN","sponsor":"The First Hospital of Jilin University","startDate":"2020-12-20","conditions":"Chemotherapy-induced Neutropenia, Lymphoma","enrollment":170},{"nctId":"NCT05409547","phase":"PHASE4","title":"A Clinical Study of Autologous Peripheral Blood Stem Cell Mobilization for PEG-G-CSF","status":"UNKNOWN","sponsor":"Ning Huang","startDate":"2022-06-30","conditions":"Granulocyte Colony-stimulating Factor, Stem Cell Mobilization","enrollment":80},{"nctId":"NCT04466137","phase":"PHASE3","title":"Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy","status":"COMPLETED","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2020-10-16","conditions":"Non-Myeloid Malignancy","enrollment":398},{"nctId":"NCT05222009","phase":"PHASE1","title":"G-CSF in Patients With Anti-PD-1-axis Therapy-resistant Recurrent or Metastatic Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2022-01-24","conditions":"Granulocyte Colony-Stimulating Factor, PD-1 Inhibitor","enrollment":25},{"nctId":"NCT05222035","phase":"PHASE2","title":"PD-1 Inhibitor Plus G-CSF in Recurrent/Metastatic NPC With First-line Treatment Failure","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2022-01-24","conditions":"PD-1 Inhibitor, G-CSF","enrollment":68},{"nctId":"NCT05156554","phase":"NA","title":"PEG-rhG-CSF Compared With rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2021-12","conditions":"Lymphoma","enrollment":80},{"nctId":"NCT04547829","phase":"PHASE2","title":"Safety and Efficacy of PEG-rhG-CSF in Preventing Neutropenia in Children With Tumor After Chemotherapy","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-10-10","conditions":"Pediatric Cancer","enrollment":108},{"nctId":"NCT04773327","phase":"NA","title":"Efficacy and Safety of PEG-rhG-CSF in the Prevention of Neutropenia After Chemo in Pts With Gynecological Malignancies","status":"UNKNOWN","sponsor":"Xiaohua Wu MD","startDate":"2021-05","conditions":"Gynecologic Malignant Tumor","enrollment":150},{"nctId":"NCT04009941","phase":"PHASE4","title":"Efficacy and Safety of 4.5mg PEG-rhG-CSF Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer","status":"COMPLETED","sponsor":"Peking University","startDate":"2019-08-01","conditions":"Breast Cancer, Neutropenia","enrollment":104},{"nctId":"NCT04518800","phase":"NA","title":"PEG-rhG-CSF in Secondary Prevention of Nab-Paclitaxel Combined With S-1 in Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2020-08-18","conditions":"PEG-rhG-CSF, Pancreatic Cancer","enrollment":20},{"nctId":"NCT04500886","phase":"NA","title":"Evaluate the Efficacy and Safety of PEG-rhG-CSF in Patients With Hemophagocytic Syndrome","status":"UNKNOWN","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2020-08-01","conditions":"Hemophagocytic Syndrome","enrollment":50},{"nctId":"NCT04497688","phase":"NA","title":"Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2019-01-01","conditions":"Non Hodgkin's Lymphoma","enrollment":104},{"nctId":"NCT04497701","phase":"NA","title":"Evaluate the Efficacy and Safety of the Prophylactic Use of PEG-rhG-CSF in Children With Hematological Malignancies","status":"UNKNOWN","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2020-08-01","conditions":"Lymphoma, Leukemia","enrollment":139},{"nctId":"NCT04239001","phase":"NA","title":"Efficacy and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor in Secondary Prevention of Albumin Paclitaxel Combined With S-1 in the First-line Treatment of Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2020-02","conditions":"Advanced Pancreatic Cancer","enrollment":20},{"nctId":"NCT04083079","phase":"PHASE4","title":"Cost-Effectiveness Study of PEG-rhG-CSF in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2019-08-01","conditions":"Lymphoma, Non-Hodgkin, Granulocyte Colony-Stimulating Factor, Cost-Benefit Analysis","enrollment":250},{"nctId":"NCT03870412","phase":"NA","title":"Evaluation of the Application of PEGylated Recombinant Human Granulocyte Stimulating Factor Injection (PEG-rhG-CSF) in Chemotherapy of Elderly Lymphoma Patients","status":"UNKNOWN","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2019-02-22","conditions":"Elderly Lymphoma Patients","enrollment":485},{"nctId":"NCT03846414","phase":"","title":"Real World Study of PEG-rhG-CSF in Prevention of Chemotherapy-induced Neutropenia","status":"UNKNOWN","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2019-02-13","conditions":"Chemotherapy-induced Neutropenia, Myelosuppression","enrollment":1500},{"nctId":"NCT02944604","phase":"PHASE4","title":"The Efficacy and Safety of PEG-rhG-CSF（Pegylated Recombinant Human Granulocyte Colony Stimulating Factor)in Patients With Breast Cancer Who Were Treated With Intensive Chemotherapy","status":"COMPLETED","sponsor":"Peking University","startDate":"2016-09-08","conditions":"Breastcancer","enrollment":240},{"nctId":"NCT03798665","phase":"","title":"A Real World Study Evaluating the Clinical Application of PEG-rhG-CSF During Chemotherapy in Patients With Solid Tumors","status":"UNKNOWN","sponsor":"Affiliated Hospital of North Sichuan Medical College","startDate":"2018-07-06","conditions":"Neutropenia","enrollment":800},{"nctId":"NCT03618810","phase":"","title":"Prophylactic Use of PEG-rhG-CSF in Medium-high Risk of FN in Chemotherapy of Breast Cancer","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2019-01-20","conditions":"Febrile Neutropenia","enrollment":2000},{"nctId":"NCT03776604","phase":"NA","title":"PEG-rhG-CSF in Elderly Patients With Small Cell Lung Cancer Receiving Chemotherapy","status":"UNKNOWN","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2018-12-05","conditions":"Small Cell Lung Cancer, PEG-rhG-CSF","enrollment":61},{"nctId":"NCT03731442","phase":"PHASE3","title":"Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients","status":"RECRUITING","sponsor":"Chinese Academy of Medical Sciences","startDate":"2018-11-01","conditions":"Esophageal Cancer","enrollment":300},{"nctId":"NCT03701841","phase":"","title":"Efficacy, Safety and Cost-effectiveness of PEG-rhG-CSF for Primary vs Secondary Prophylaxis","status":"UNKNOWN","sponsor":"Anhui Provincial Hospital","startDate":"2018-10","conditions":"Chemotherapy-induced Neutropenia","enrollment":1000},{"nctId":"NCT02005458","phase":"PHASE2","title":"Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy","status":"COMPLETED","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2013-12","conditions":"Non Small Cell Lung Cancer, Breast Cancer","enrollment":80},{"nctId":"NCT03206229","phase":"PHASE1","title":"Study Comparing TPI-120 and Neulasta Administered Through Subcutaneous Route in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Adello Biologics, LLC","startDate":"2017-02-13","conditions":"Healthy Volunteers","enrollment":120},{"nctId":"NCT03206684","phase":"PHASE4","title":"To Evaluate the Efficacy and Safety of PEG-rhG-CSF（Jinyouli®） in Reducing Neutropenia in Patients With Cervical Cancer","status":"UNKNOWN","sponsor":"Air Force Military Medical University, China","startDate":"2017-08","conditions":"Cervical Cancer","enrollment":20},{"nctId":"NCT02761460","phase":"PHASE3","title":"The Efficacy and Safety of PEG-rhG-CSF in Preventing Chemotherapy-induced Neutropenia","status":"UNKNOWN","sponsor":"wang shusen","startDate":"2016-05-04","conditions":"Breast Cancer","enrollment":338},{"nctId":"NCT02996617","phase":"PHASE4","title":"PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia","status":"UNKNOWN","sponsor":"Shandong Provincial Hospital","startDate":"2016-11","conditions":"Lymphoma,Non-Hodgkin","enrollment":240},{"nctId":"NCT02953730","phase":"PHASE4","title":"The Study on the Pharmacokinetics of PEG-rhG-CSF in Children and Adolescents","status":"COMPLETED","sponsor":"Chinese Academy of Medical Sciences","startDate":"2015-09","conditions":"Acute Lymphoid Leukemia","enrollment":9},{"nctId":"NCT02905942","phase":"PHASE4","title":"PEG-rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Peking University","startDate":"2015-12","conditions":"Lymphoma","enrollment":96},{"nctId":"NCT02905916","phase":"PHASE4","title":"The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy","status":"UNKNOWN","sponsor":"Peking University","startDate":"2016-06","conditions":"Mammary Cancer, Lymphoma, Bone Tumour","enrollment":217},{"nctId":"NCT02805218","phase":"PHASE4","title":"PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy","status":"COMPLETED","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2013-09","conditions":"Lymphoma","enrollment":410},{"nctId":"NCT02805153","phase":"PHASE4","title":"PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy","status":"COMPLETED","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2013-04","conditions":"Breast Cancer","enrollment":215},{"nctId":"NCT02805205","phase":"PHASE4","title":"PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy to Prevent Neutropenia","status":"COMPLETED","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2013-04","conditions":"Breast Cancer","enrollment":484},{"nctId":"NCT02805166","phase":"PHASE4","title":"PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy","status":"COMPLETED","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2013-04","conditions":"Malignant Solid Tumors","enrollment":420},{"nctId":"NCT01859637","phase":"PHASE4","title":"Immunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia","status":"TERMINATED","sponsor":"Sandoz","startDate":"2011-07","conditions":"Severe Chronic Neutropenia","enrollment":6},{"nctId":"NCT01918241","phase":"PHASE2","title":"Saftey and Efficacy of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia","status":"UNKNOWN","sponsor":"Hangzhou Jiuyuan Gene Engineering Co. Ltd.,","startDate":"2013-07","conditions":"Neutropenia","enrollment":200},{"nctId":"NCT02119715","phase":"PHASE2","title":"A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2011-02","conditions":"Breast Cancer, Neutropenia, Febrile Neutropenia","enrollment":182},{"nctId":"NCT00501228","phase":"NA","title":"Tissue Repair in Stem Cell Transplant Recipients","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2003-02","conditions":"Graft-Versus-Host Disease","enrollment":2},{"nctId":"NCT00809549","phase":"PHASE1","title":"Study to Determine The Effect of a Drug Called Neupogen on Stroke Recovery","status":"UNKNOWN","sponsor":"Ottawa Hospital Research Institute","startDate":"2006-07","conditions":"Ischemic Stroke","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"rhG-CSF/PEG-rhG-CSF","genericName":"rhG-CSF/PEG-rhG-CSF","companyName":"Xiamen Amoytop Biotech Co., Ltd.","companyId":"xiamen-amoytop-biotech-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"rhG-CSF/PEG-rhG-CSF is a protein-based treatment used to stimulate the production of white blood cells, particularly granulocytes, in patients undergoing intensive chemotherapy for breast cancer. It has been studied in clinical trials for various conditions, including graft-versus-host disease and gynecologic malignant tumors, in addition to its use in breast cancer treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}